Editorial on the relationship between suPAR and CKD, published in NEJM
Wed Oct 21 2020
“A suPAR Biomarker for Chronic Kidney Disease”, published in the New England Journal of Medicine
The worldwide epidemic of Chronic Kidney Disease constitutes a death sentence in regions of the world where renal-replacement therapies are not available. Since decreased renal function is only detected after substantial kidney injury has already occurred, there is an urgent need to identify new biomarkers that accurately determine the risk of impending chronic kidney disease while renal function is still well preserved and there is higher likelihood that medical interventions can slow or prevent progression.
Studies that show that intervention based on suPAR levels is beneficial could cement a relationship between suPAR and chronic kidney disease.